Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Market Cap & Net Worth: Welgene Biotech Co.Ltd. (6661)
Welgene Biotech Co.Ltd. (TWO:6661) has a market capitalization of $13.21 Million (NT$436.95 Million) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #32703 globally and #1885 in its home market, demonstrating a 1.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Welgene Biotech Co.Ltd.'s stock price NT$18.75 by its total outstanding shares 23304248 (23.30 Million).
Welgene Biotech Co.Ltd. Market Cap History: 2017 to 2026
Welgene Biotech Co.Ltd.'s market capitalization history from 2017 to 2026. Data shows change from $12.40 Million to $13.21 Million (-2.29% CAGR).
Welgene Biotech Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Welgene Biotech Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Welgene Biotech Co.Ltd.'s market cap is 0.05 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
15.14x
Welgene Biotech Co.Ltd.'s market cap is 15.14 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $12.40 Million | $325.78 Million | $23.65 Million | 0.04x | 0.52x |
| 2018 | $11.98 Million | $384.43 Million | $28.34 Million | 0.03x | 0.42x |
| 2019 | $17.40 Million | $417.46 Million | $30.87 Million | 0.04x | 0.56x |
| 2020 | $23.73 Million | $398.10 Million | $29.77 Million | 0.06x | 0.80x |
| 2021 | $16.69 Million | $312.65 Million | $13.70 Million | 0.05x | 1.22x |
| 2022 | $15.51 Million | $321.90 Million | $9.55 Million | 0.05x | 1.62x |
| 2023 | $15.74 Million | $280.55 Million | -$2.65 Million | 0.06x | N/A |
| 2024 | $16.76 Million | $322.55 Million | $1.11 Million | 0.05x | 15.14x |
Competitor Companies of 6661 by Market Capitalization
Companies near Welgene Biotech Co.Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Welgene Biotech Co.Ltd. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Welgene Biotech Co.Ltd. Historical Marketcap From 2017 to 2026
Between 2017 and today, Welgene Biotech Co.Ltd.'s market cap moved from $12.40 Million to $ 13.21 Million, with a yearly change of -2.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$13.21 Million | +0.81% |
| 2025 | NT$13.10 Million | -21.85% |
| 2024 | NT$16.76 Million | +6.49% |
| 2023 | NT$15.74 Million | +1.49% |
| 2022 | NT$15.51 Million | -7.05% |
| 2021 | NT$16.69 Million | -29.68% |
| 2020 | NT$23.73 Million | +36.39% |
| 2019 | NT$17.40 Million | +45.17% |
| 2018 | NT$11.98 Million | -3.38% |
| 2017 | NT$12.40 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Welgene Biotech Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.21 Million USD |
| MoneyControl | $13.21 Million USD |
| MarketWatch | $13.21 Million USD |
| marketcap.company | $13.21 Million USD |
| Reuters | $13.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.